The standard-of-care thinking on TAVR has shifted from getting a valve implanted and managing immediate complications to looking decades down the road and considering the patient's long-term health. 

New research, published in JAMA Cardiology, challenges the common belief that AFib is more likely to develop among men than women. The key problem, it seems, is that prior research teams did not understand the significance of certain risk factors.

A new consensus statement from the Society of Cardiovascular Computed Tomography emphasized the increasing importance of CCTA among interventional cardiologists. It is no longer seen as “a mere diagnostic tool," the group observed. 

The promising results were presented at ESC Congress 2022 and published in the New England Journal of Medicine. Medtronic's new-look device is not yet approved for sale or distribution. 

ESC Congress 2022, the annual meeting of the European Society of Cardiology, was jam-packed with eye-opening new research from many of the leading voices in cardiovascular and vascular medicine. These six sessions were just some of the weekend's many highlights. 

Elderly patients are often not eligible for oral anticoagulant therapy due to the risk of bleeding events or other adverse outcomes. A very low dose of edoxaban, however, appears to be a safe treatment option, even for especially frail patients.

A care team with the Sanger Heart & Vascular Institute has shared details about its recent successes in TMVR and TAVR. Cardiologist Michael Rinaldi, MD, highlighted the importance of having "a coordinated team of specialists with expertise in treating valve diseases."

The all-day summit, a collaboration between CRF and Fogarty Innovation, will focus on advances in healthcare technologies and patient care.